Mathematical Modeling-based Medication for Minimizing Malignant evolution of Lung Cancer
- Conditions
- EGFR mutation-positive lung adenocarcinoma
- Registration Number
- JPRN-UMIN000032248
- Lead Sponsor
- Sendai Kosei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5
Not provided
1) History of any type of malignancy within the past 5 years (including carcinoma in situ). 2) History of organ transplantation (including hematopoietic stem cell transplantation) 3) Major surgery within one month prior to the first blood sampling in this study. 4) Radiotherapy for brain metastatic or other locally advanced lesions within two weeks prior to the first blood sampling in this study. 5) Concomitant presence of distinct types of lung cancer is confirmed: - Patients with histologically distinct types of lung cancer, including lung squamous cell carcinoma and small cell lung cancer, will be excluded. - Patients with distinct lung adenocarcinomas harboring ALK translocation or ROS1 translocation will be excluded.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mathematical modeling to understand the dynamics of lung cancer evolution.
- Secondary Outcome Measures
Name Time Method